Martin H Bolli

5PUBLICATIONS
14CO-AUTHORS
GlycoconjugatesBiomolecular modelling and designSensory systemsCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 12, 2025
Discovery of Galactopyranose-1-carboxamides as a New Class of Small, Novel, Potent, Selective, and Orally Active Galectin-3 Inhibitors.

Cornelia Zumbrunn, Luboš Remen, Christoph P Sager

|Feb 13, 2024
Discovery of the Novel, Orally Active, and Selective LPA1 Receptor Antagonist ACT-1016-0707 as a Preclinical Candidate for the Treatment of Fibrotic Diseases.

Cyrille Lescop, Magdalena Birker, Christine Brotschi

|Feb 13, 2024
Discovery of a Novel Orally Active, Selective LPA Receptor Type 1 Antagonist, 4-(4-(2-Isopropylphenyl)-4-((2-methoxy-4-methylphenyl)carbamoyl)piperidin-1-yl)-4-oxobutanoic Acid, with a Distinct Molecular Scaffold.

Cyrille Lescop, Christine Brotschi, Jodi T Williams

|Feb 08, 2024
Discovery of Nivasorexant (ACT-539313): The First Selective Orexin-1 Receptor Antagonist (SO1RA) Investigated in Clinical Trials.

Jodi T Williams, Martin H Bolli, Christine Brotschi

|Jan 29, 2024
Pyrazole derivatives as selective orexin-2 receptor antagonists (2-SORA): synthesis, structure-activity-relationship, and sleep-promoting properties in rats.

Christine Brotschi, Martin H Bolli, John Gatfield

Pageof 1

Frequent Collaborators

3 joint publications

Jodi T Williams

2 joint publications

Christine Brotschi

2 joint publications

John Gatfield

2 joint publications

Christoph P Sager